Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Cellectis SA (CLLS) Stock Price & Analysis
830 Followers
CLLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $4.04
Previous Close$1.35
Volume7.49K
Average Volume (3M)61.40K
Market Cap
$71.26M
Enterprise Value$46.68M
Total Cash (Recent Filing)$89.79M
Total Debt (Recent Filing)$57.23M
Price to Earnings (P/E)-0.7
Beta1.44
Next Earnings
Nov 09, 2023EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding45,675,968
10 Day Avg. Volume69,362
30 Day Avg. Volume61,403
Standard Deviation0.19
R-Squared0.37
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.11
Price to Sales (P/S)3.22
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.31
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$8.50Price Target Upside539.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Cellectis SA News
Stock Analysis & IdeasThese 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says...
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.33 and its highest was $4.04 in the past 12 months.
What is Cellectis SA’s market cap?
Currently, no data Available
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2023 which is in 21 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 03, 2023. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.248.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -$0.42.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 55,583,767 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went down -5.128%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 4M.
---
Cellectis SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (539.10% Upside)
$8.50 (539.10% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.56%
12-Months-Change
Fundamentals
Return on Equity
-62.38%
Trailing 12-Months
Asset Growth
-29.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cellectis SA
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
---
Top 5 ETFs holding CLLS
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold CLLS. The ETFs are listed according to market value of CLLS within the ETF
BioMarin Pharmaceutical
―
Adverum Biotechnologies
―
Bluebird Bio
―
Crispr Therapeutics AG
―
---